Total Payments
$1.1M
2024 Payments
$188,650
Companies
46
Transactions
1,606
Medicare Patients
3,372
Medicare Billing
$677,400
Payment Breakdown by Category
Other$939,410 (81.9%)
Consulting$97,718 (8.5%)
Travel$85,412 (7.4%)
Food & Beverage$23,439 (2.0%)
Education$1,018 (0.1%)
Research$75.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $933,950 | 360 | 81.4% |
| Consulting Fee | $97,718 | 41 | 8.5% |
| Travel and Lodging | $85,412 | 314 | 7.4% |
| Food and Beverage | $23,439 | 871 | 2.0% |
| Honoraria | $5,460 | 1 | 0.5% |
| Education | $1,018 | 18 | 0.1% |
| Unspecified | $75.00 | 1 | 0.0% |
Payments by Type
General
$1.1M
1,605 transactions
Research
$75.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $334,817 | 373 | $0 (2024) |
| Biogen, Inc. | $260,474 | 340 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $109,073 | 158 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $90,682 | 146 | $0 (2022) |
| TG Therapeutics, Inc. | $76,017 | 61 | $0 (2024) |
| ABBVIE INC. | $70,517 | 127 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $64,892 | 82 | $0 (2024) |
| ARGENX US, INC. | $48,503 | 80 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $22,332 | 30 | $0 (2023) |
| Acorda Therapeutics, Inc | $17,510 | 13 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $188,650 | 227 | TG Therapeutics, Inc. ($75,930) |
| 2023 | $106,580 | 180 | Biogen, Inc. ($26,837) |
| 2022 | $120,041 | 180 | Biogen, Inc. ($29,860) |
| 2021 | $121,777 | 169 | GENZYME CORPORATION ($33,581) |
| 2020 | $87,986 | 117 | Biogen, Inc. ($28,639) |
| 2019 | $190,882 | 273 | GENZYME CORPORATION ($62,167) |
| 2018 | $154,110 | 198 | GENZYME CORPORATION ($77,215) |
| 2017 | $177,046 | 262 | GENZYME CORPORATION ($76,794) |
All Payment Transactions
1,606 individual payment records from CMS Open Payments — Page 1 of 65
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: NEUROSCIENCE | ||||||
| 12/19/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,875.00 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/19/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | Cash or cash equivalent | $17.49 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/12/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,387.50 | General |
| Category: Immunology | ||||||
| 12/12/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Travel and Lodging | Cash or cash equivalent | $162.40 | General |
| Category: Immunology | ||||||
| 12/12/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $41.91 | General |
| Category: Immunology | ||||||
| 12/09/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,737.50 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/09/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Travel and Lodging | Cash or cash equivalent | $486.20 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/09/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Travel and Lodging | Cash or cash equivalent | $170.17 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/09/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | Cash or cash equivalent | $27.43 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/05/2024 | Biogen, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,152.00 | General |
| 12/05/2024 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | Cash or cash equivalent | $22.00 | General |
| Category: Neurology | ||||||
| 12/04/2024 | Biogen, Inc. | TYSABRI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,918.00 | General |
| Category: Neurology | ||||||
| 12/04/2024 | Biogen, Inc. | TYSABRI (Biological) | Travel and Lodging | In-kind items and services | $1,164.00 | General |
| Category: Neurology | ||||||
| 12/04/2024 | Biogen, Inc. | TYSABRI (Biological) | Travel and Lodging | In-kind items and services | $173.00 | General |
| Category: Neurology | ||||||
| 12/04/2024 | Biogen, Inc. | TYSABRI (Biological) | Travel and Lodging | Cash or cash equivalent | $38.00 | General |
| Category: Neurology | ||||||
| 12/04/2024 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | Cash or cash equivalent | $16.00 | General |
| Category: Neurology | ||||||
| 12/04/2024 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | Cash or cash equivalent | $15.00 | General |
| Category: Neurology | ||||||
| 12/03/2024 | ARGENX US, INC. | VYVGART (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: Immunology | ||||||
| 12/03/2024 | ARGENX US, INC. | VYVGART (Drug) | Travel and Lodging | Cash or cash equivalent | $75.67 | General |
| Category: Immunology | ||||||
| 12/03/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $59.51 | General |
| Category: Immunology | ||||||
| 12/03/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: Neurology | ||||||
| 11/25/2024 | ARGENX US, INC. | VYVGART (Drug) | Travel and Lodging | Cash or cash equivalent | $701.95 | General |
| Category: Immunology | ||||||
| 11/25/2024 | ARGENX US, INC. | VYVGART (Drug) | Travel and Lodging | Cash or cash equivalent | $80.00 | General |
| Category: Immunology | ||||||
| 11/22/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $31.90 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MS200527-0073 | EMD Serono, Inc. | $75.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 826 | 17,963 | $680,348 | $175,203 |
| 2022 | 9 | 757 | 19,198 | $611,483 | $170,725 |
| 2021 | 9 | 896 | 17,038 | $527,820 | $170,398 |
| 2020 | 9 | 893 | 18,118 | $543,428 | $161,073 |
Total Patients
3,372
Total Services
72,317
Medicare Billing
$677,400
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 27 | 16,900 | $153,959 | $82,960 | 53.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 182 | 292 | $204,984 | $35,225 | 17.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 176 | 203 | $101,297 | $16,957 | 16.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 104 | 104 | $89,128 | $16,143 | 18.1% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 25 | 81 | $47,061 | $9,199 | 19.5% |
| 92283 | Extended exam involving color vision testing | Office | 2023 | 84 | 105 | $21,945 | $4,214 | 19.2% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 90 | 105 | $25,620 | $4,204 | 16.4% |
| 92133 | Imaging of optic nerve | Office | 2023 | 115 | 150 | $21,450 | $3,845 | 17.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $14,904 | $2,457 | 16.5% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 30 | 18,200 | $160,647 | $83,584 | 52.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 165 | 252 | $156,082 | $30,884 | 19.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 188 | 251 | $109,502 | $19,739 | 18.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 92 | 92 | $70,096 | $13,717 | 19.6% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2022 | 28 | 89 | $48,355 | $9,826 | 20.3% |
| 92083 | Exam of visual field with extended testing | Office | 2022 | 73 | 97 | $21,740 | $4,183 | 19.2% |
| 92133 | Imaging of optic nerve | Office | 2022 | 94 | 122 | $16,172 | $3,114 | 19.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 24 | 24 | $14,890 | $2,895 | 19.4% |
| 92283 | Extended exam involving color vision testing | Office | 2022 | 63 | 71 | $13,999 | $2,783 | 19.9% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 30 | 15,920 | $143,280 | $73,183 | 51.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 262 | 355 | $117,860 | $29,090 | 24.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 134 | 183 | $81,984 | $22,564 | 27.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 99 | 99 | $63,360 | $16,575 | 26.2% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2021 | 26 | 76 | $35,188 | $8,485 | 24.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 64 | 64 | $32,640 | $7,974 | 24.4% |
| 92083 | Measurement of field of vision during daylight conditions, extended examination | Office | 2021 | 85 | 108 | $21,596 | $5,015 | 23.2% |
About Dr. David Clark, DO
Dr. David Clark, DO is a Neurology healthcare provider based in Springfield, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2007. The National Provider Identifier (NPI) number assigned to this provider is 1578760278.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Clark, DO has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $188,650 received in 2024. These payments were reported across 1,606 transactions from 46 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($933,950).
As a Medicare-enrolled provider, Clark has provided services to 3,372 Medicare beneficiaries, totaling 72,317 services with total Medicare billing of $677,400. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology
- Location Springfield, OR
- Active Since 06/27/2007
- Last Updated 05/13/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1578760278
Products in Payments
- AUBAGIO (Drug) $201,235
- TECFIDERA (Drug) $94,165
- BRIUMVI (Drug) $76,000
- TYSABRI (Biological) $69,069
- VUMERITY (Drug) $62,288
- UBRELVY (Drug) $57,735
- MAYZENT (Drug) $50,143
- VYVGART (Drug) $48,256
- LEMTRADA (Drug) $45,559
- COPAXONE (Drug) $36,089
- ULTOMIRIS (Biological) $29,408
- ZEPOSIA (Drug) $22,598
- Soliris (Drug) $17,714
- AMPYRA (Drug) $17,469
- AJOVY (Biological) $16,385
- SOLIRIS (Biological) $13,196
- Ponvory (Drug) $13,053
- QULIPTA (Drug) $12,719
- AJOVY (Drug) $12,235
- PONVORY (Drug) $8,277
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Springfield
Raymond Englander, Md, MD
Neurology — Payments: $167,481
Neurology $167,481
Dr. Jenifer Zhai, Md, MD
Neurology — Payments: $121,314
Neurology $121,314
Cecile Becker, M.d, M.D
Neurology — Payments: $78,042
Neurology $78,042
Jennifer Lynch, Md, MD
Neurology — Payments: $73,454
Neurology $73,454
Jayant Acharya, Md, MD
Neurology — Payments: $56,046
Neurology $56,046
Rodger Elble, M.d, M.D
Neurology — Payments: $52,657
Neurology $52,657